Payment overview · 2025
General Payments
$143.64
6 reported records · 4 companies
Healthcare provider profile · identity verified
Youssef Behnam Awad, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LONG BEACH, CA · NPI 1164528105
Verified facts
What the public records show
CMS Open Payments records show Youssef Behnam Awad, MD received $143.64 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 56.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rinvoq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $81.15 | 56.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.94 | 16.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.84 | 16.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.71 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $143.64 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.15 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $38.55 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 118 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 81 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 147 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
147 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
118 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 808 | 111 |
| Metformin Hcl | Metformin Hcl | 744 | 113 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 684 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 585 | 82 |
| Fluticasone Propionate | Fluticasone Propionate | 557 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 555 | 61 |
| Losartan Potassium | Losartan Potassium | 534 | 80 |
| Gabapentin | Gabapentin | 513 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 474 | 66 |
| Famotidine | Famotidine | 456 | 68 |
| Diclofenac Sodium | Diclofenac Sodium | 403 | 61 |
| Omeprazole | Omeprazole | 369 | 41 |
| Ibuprofen | Ibuprofen | 339 | 47 |
| Lisinopril | Lisinopril | 337 | 47 |
| Ketoconazole | Ketoconazole | 298 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 275 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 250 | 30 |
| Naproxen | Naproxen | 237 | 32 |
| Furosemide | Furosemide | 225 | 34 |
| Alendronate Sodium | Alendronate Sodium | 213 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 24 |
| Ozempic | Semaglutide | 161 | 17 |
| Eliquis | Apixaban | 155 | 21 |
| Azithromycin | Azithromycin | 153 | 86 |
| Meclizine Hcl | Meclizine Hcl | 153 | 20 |
| Sertraline Hcl | Sertraline Hcl | 149 | 21 |
| Linzess | Linaclotide | 147 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 139 | 19 |
| Clonidine Hcl | Clonidine Hcl | 134 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 21 |
| Glipizide | Glipizide | 119 | 21 |
| Farxiga | Dapagliflozin Propanediol | 118 | 18 |
| Ondansetron Odt | Ondansetron | 108 | 26 |
| Januvia | Sitagliptin Phosphate | 103 | 16 |
| Lidocaine | Lidocaine | 102 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 11 |
| Carvedilol | Carvedilol | 96 | 18 |
| Myrbetriq | Mirabegron | 95 | 12 |
| Hydrocortisone | Hydrocortisone | 88 | 12 |
| Finasteride | Finasteride | 83 | 13 |
| Levetiracetam | Levetiracetam | 83 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | 12 |
| Jardiance | Empagliflozin | 81 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 81 | suppressed |
| Simvastatin | Simvastatin | 79 | 11 |
| Montelukast Sodium | Montelukast Sodium | 78 | 12 |
| Lactulose | Lactulose | 76 | suppressed |
| Allopurinol | Allopurinol | 73 | 11 |
| Trazodone Hcl | Trazodone Hcl | 72 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 71 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 13 |
| Metformin Hcl Er | Metformin Hcl | 66 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | suppressed |
| Potassium Chloride | Potassium Chloride | 63 | 11 |
| Baclofen | Baclofen | 55 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | suppressed |
| Meloxicam | Meloxicam | 53 | suppressed |
| Prednisone | Prednisone | 52 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 52 | suppressed |
| Cyclosporine | Cyclosporine | 51 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 45 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Celecoxib | Celecoxib | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 42 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 41 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Loperamide | Loperamide Hcl | 37 | 15 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Metronidazole | Metronidazole | 31 | 20 |
| Temazepam | Temazepam | 31 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Procto-Med Hc | Hydrocortisone | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 23 | 16 |
| Restasis | Cyclosporine | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Proctozone-Hc | Hydrocortisone | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 11 |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Xiidra | Lifitegrast | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Rinvoq | Upadacitinib | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $143.64 · 6 records | AstraZeneca Pharmaceuticals LP | FARXIGA, JARDIANCE, LINZESS, VIBERZI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error